LXEO
Lexeo Therapeutics, Inc. Common Stock · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +6.7% ·
share flow +14.7% ·
net new positions +6.2%
— formula
Broad accumulation — rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 64 | +3 | 35.14M | $163.68M | +8 | −5 |
| Q1 2026 | 64 | -1 | 34.99M | $201.02M | +4 | −5 |
| Q4 2025 | 65 | +1 | 34.14M | $338.98M | +1 | — |
| Q3 2025 | 16 | +1 | 14.53M | $96.47M | +1 | — |
| Q2 2025 | 12 | -2 | 12.40M | $49.85M | — | −2 |
| Q1 2025 | 11 | +1 | 6.39M | $22.16M | +2 | −1 |
| Q4 2024 | 10 | +3 | 6.97M | $45.84M | +3 | — |
| Q3 2024 | 6 | +1 | 6.33M | $57.26M | +1 | — |
| Q2 2024 | 5 | — | 5.51M | $88.42M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Citadel Advisors ✦ | 3.72M | +3.1% | $24.69M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 2 | Millennium Management ✦ | 2.31M | -18.4% | $15.36M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 3 | The Vanguard Group ✦ (passive) | 2.23M | +11.2% | $14.78M | 0.0% | ▲ Add | 2 | SEC ↗ ×3 |
| 4 | BlackRock ✦ (passive) | 2.17M | +18.8% | $14.42M | 0.0% | ▲ Add | 2 | SEC ↗ ×7 |
| 5 | Point72 Asset Management ✦ | 1.94M | +199.7% | $12.89M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 6 | Geode Capital Management ✦ (passive) | 721.88K | +24.9% | $4.79M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 7 | State Street Global Advisors ✦ (passive) | 544.85K | +6.2% | $3.62M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 8 | AQR Capital Management ✦ | 347.92K | +84.4% | $2.31M | 0.0% | ▲ Add | 4 | SEC ↗ ×5 |
| 9 | Renaissance Technologies ✦ | 149.30K | +40.6% | $991,352 | 0.0% | ▲ Add | 3 | SEC ↗ |
| 10 | Goldman Sachs Group ✦ | 142.40K | — | $945,549 | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 11 | Morgan Stanley ✦ | 98.06K | — | $651,097 | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 12 | Two Sigma Investments ✦ | 84.76K | +22.4% | $562,826 | 0.0% | ▲ Add | 3 | SEC ↗ |
| 13 | JPMorgan Chase ✦ | 28.72K | — | $190,688 | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 14 | Fidelity (FMR) ✦ | 13.43K | +14.3% | $89,195 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 15 | D. E. Shaw & Co. ✦ | 12.82K | New | $85,112 | 0.0% | New | 1 | SEC ↗ |
| 16 | T. Rowe Price ✦ | 11.96K | +14.8% | $80,000 | 0.0% | ▲ Add | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| D. E. Shaw & Co. | $85,112 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 137 holders, 79.80M shares, $457.81M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 3.35K sh · $16,562
Officer · 1.30K sh · $6,464
Officer · 4.12K sh · $20,203
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology